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2. Introduction
2.1 Hepatoblastoma
2.1.1 Epidemiology
Hepatoblastoma (HB) is a rare pediatric tumor originating from the liver. Although it is the 
most common hepatic malignancy in children, it only makes up just over 1% of all pediatric 
neoplasms1.  The annual incidence lies somewhere around 1.2-1.5 cases per million chil-
dren under the age of 15 in Western countries, with almost all cases occurring under the 
age	of	five2, 3.  The incidence of HB in males is higher than in females with a reported male 
to female ratio ranging from 1.2 to 3.34. 
Several syndromes are associated with a higher incidence of HB. Familial adenomatous 
polyposis coli (FAP) is a syndrome caused by the mutation of the adenomatous polyposis 
coli (APC) gene and is characterized by early development of colon cancer5. Children with 
FAP	are	at	higher	risk	of	developing	HB	especially	in	the	first	four	years	of	their	lives	com-
pared to the general population6.
Beckwith–Wiedemann Syndrome (BWS) is an overgrowth syndrome caused by imprinting 
defects at the loci of several genes7. Patients usually present with large birth weight, mac-
roglossia, and large abdominal organs. BWS is associated with a number of embryonal 
malignancies such as Wilms tumor, neuroblastoma and HB8.
Various other syndromes are also associated with increased HB incidences and include 
trisomy 18, Simpson–Golabi–Behmel syndrome, Prader–Willi syndrome, Sotos syndrome, 
Kabuki	syndrome,	Neurofibromatosis	type	1,	Fanconi	Anemia,	Tyrosinemia	type	1,	Noonan	
syndrome and DiGeorge syndrome9. The molecular mechanisms by which those syn-
dromes might promote HB development remain poorly understood. 
Several studies also looked for environmental risk factors during pregnancy that might be 
triggering HB development. The only consistent factors found to be associated with an in-
creased HB incidence were low birth weight and prematurity9, 10. 
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2.1.2 Clinical presentation and diagnosis
Patients with HB commonly present with abdominal distension or a palpable abdominal 
mass. More general symptoms include fatigue, abdominal pain and discomfort, loss of 
appetite, failure to thrive and occasionally jaundice11, 12. Ultrasonography usually reveals 
a large hepatic mass and a subsequent abdominal MRI is able to expose the full extend 
of tumor growth. Additional imaging is performed to look for metastasis, which are found 
almost exclusively in the lungs13. In at least 70% of HB patients elevated serum alpha feto 
protein (AFP) level can be detected. AFP serves as a useful marker for diagnosis and risk 
stratification	and	is	also	used	for	monitoring	tumor	response	to	therapy.	Depending	on	the	
risk	stratification	of	 the	patients	 (see	below)	a	percutaneous	biopsy	of	 the	 liver	mass	or	
metastatic lesions might be appropriate4, 11. 
2.1.3 Histology
HB is an embryonal tumor that is believed to originate from early hepatocyte precursor 
cells14. Its histological patterns resemble various stages of liver development and can be di-
vided in two major histological subtypes2. The more predominant epithelial subtype makes 
up about 56% of HBs and can be further subdivided into pure fetal, embryonal, macrotra-
becular, small cell undifferentiated and cholangioblastic4. The mixed subtype makes up 
44% of HBs and comprises epithelial and mesenchymal features. Tumors of the mixed sub-
group can contain stromal derivatives or display teratoid features. Histopathological char-
acterization of HB tissue is not only important for diagnostic purposes, but is also prognos-
tically relevant15. Although tumors are rarely composed of only one histological type it can 
be stated, that tumors displaying largely fetal histology are generally associated with better 
outcomes than those with predominant embryonal or small cell undifferentiated features16.
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2.1.4 Genetic and epigenetic background
Besides histology HB also has distinct molecular features that can be used for further 
characterization. Embryonal malignancies such as HB are believed to arise from primordial 
cells that are unable to reach their terminal differentiation due to genetic and epigenetic 
events occurring during early organ development17. Those molecular defects lead to devel-
opmental errors eventually amounting to the formation of an embryonal tumor.  
Apart from the molecular aberrations that go along with the various above-mentioned syn-
dromes	associated	with	HB,	there	are	several	other	defining	features	commonly	found	in	
HB.	One	of	the	hallmark	cytogenetic	findings	include	whole-chromosome	aneuploidy	with	
frequent additions of chromosomes 2, 8 and 20 and loss of chromosomes 4 and 1818. In ad-
dition an unbalanced recurring translocation has been described as der(4)t(1;4)(q12;q34) 
in several HB cases19. 
Furthermore, there are a number of acquired single gene alterations commonly found in 
HB. The most frequently mutated gene is CTNNB1, which encodes for the protein beta 
catenin, a key component of the Wnt signaling pathway20. This pathway plays a crucial 
role in early liver development. The CTNNB1 mutations prevent beta catenin degradation, 
therefore leading to aberrant activation of Wnt signaling and promoting the tumorigenesis 
of HB21, 22.
Another recurring feature of HB are APC mutations which can either occur as germ-line 
mutations in the context of FAP as mentioned above or appear independently as somatic 
mutations23. APC is involved in beta catenin regulation and inactivating mutations in the 
APC gene prevent beta catenin degradation, leading to a similar activation of Wnt signaling 
as with CTNNB1 mutations24. 
Less common are mutations in AXIN1 and AXIN2, which are known to interact with both 
APC	and	beta	catenin,	therefore	also	influencing	Wnt	signaling25.
In addition to those more or less frequently detected mutations, there are a number of fur-
ther alterations on a single case level26, 27.  
Aside from genetic events, epigenetic aberrations seem to play a crucial role in HB. One 
commonly found alteration is the hypermethylation of gene promoters including secret-
ed frizzled-related protein 1 (SFRP1), hedgehog-interacting protein (HHIP) and insulin-like 
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growth factor binding protein 3 (IGFBP3)28-30. The silencing of those tumor suppressor 
genes through epigenetic mechanisms leads to activation of several developmental path-
ways contributing to HB tumorigenesis. 
2.1.5	 Staging	and	molecular	risk	stratification
There are currently four major trial groups with different staging systems for HB. The In-
ternational childhood liver tumors strategy group (SIOPEL), Children’s Oncology Group 
(COG), the German Society for Pediatric Oncology and Hematology (GPOH), and the Jap-
anese Study Group for Pediatric Liver Tumors (JPTL). Recently those four groups formed 
a global coalition called the Children’s Hepatic tumors International Collaboration (CHIC) 
and	attempted	to	create	a	consensus	approach	to	staging	and	risk	stratification	for	HB10. 
Several	prognostic	relevant	features	were	identified.
Pretreatment	extension	of	disease	(PRETEXT)	is	a	system	that	identifies	four	stages	(PRE-
TEXT I-IV), which describe the involvement of liver sections by the tumor and the tumor 
extension beyond the liver assessed by diagnostic imaging. PRETEXT I-III are more local-
ized stages, generally associated with favorable outcomes, while PRETEXT IV represents 
advanced tumor extension as a feature of high-risk HB31. 
There is also consensus that very low AFP levels of less than 100 ng/mL and patients older 
than 3 years at the time of diagnosis constitute additional high-risk characteristics of HB. 
Metastatic disease and portal or hepatic venous macrovascular involvement are also asso-
ciated with poor patient outcome10.
Aside from those traditional staging criteria, molecular markers and gene expression sig-
natures	have	shown	great	value	in	the	stratification	of	HB.	In	particular,	a	16-gene	classi-
fier	has	been	shown	to	be	equally	capable	in	predicting	HB	patient	outcome	compared	to	
stratification	based	on	clinicopathological	 characteristics32.	The	classifier	 recognizes	 two	
distinct subclasses of HB. The standard-risk C1 subclass goes along with a less aggressive 
phenotype and favorable patient outcome. The high-risk C2 subclass is associated with 
advanced tumor stage, metastases, vascular invasion and poor prognosis. Although the 
16-gene	classifier	has	shown	great	potential	in	predicting	outcomes,	it	is	not	yet	routinely	
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used	for	risk	stratification,	mostly	because	the	majority	of	patients	are	stratified	and	treated	
preoperatively without undergoing percutaneous biopsies. However, as more robust and 
predictive molecular markers are discovered they are likely to play a central role in future 
stratification	and	treatment	strategies.	
2.1.6 Treatment regimens and patient outcome
Over the last decades several treatment regimens for HB have been studied within clinical 
trials conducted by the four major trial groups mentioned above15. While those groups still 
utilize different treatment protocols some general statements about those regimens can be 
made. Patients are usually treated with neoadjuvant chemotherapy followed by surgical 
resection and adjuvant chemotherapy11. The chemotherapy usually has a platinum-based 
backbone	 (cisplatin	 or	 carboplatin),	which	 can	be	 sufficient	 as	 a	monotherapy	 for	 stan-
dard-risk patients. High-risk patients are given additional chemotherapy, mainly anthracy-
clines such as doxorubicin. Patients presenting with unresectable tumors might qualify for 
liver transplantation. 
Those treatment strategies have improved patient outcomes tremendously over the last 
decades. However, even though standard-risk patients have excellent outcomes with a 
three-year overall survival rate of 95%, high-risk patients presenting with advanced tumor 
stages, vascular invasion and distant metastases still face overall survival rates of under 
60% even with aggressive treatment regimens33, 34. 
Besides the general risks of tumor resection, there are common side effects from chemo-
therapy. The dose-limiting factor of cisplatin is mostly ototoxicity and nephrotoxicity, some-
times with irreversible organ damage35, 36. Even more severe are the side effects of anthra-
cyclines in young children. Patients treated with doxorubicin are not only at risk for acute 
cardiotoxicity, they might also develop doxorubicin induced cardiomyopathy years after the 
last dose was administered37, 38. This late developed cardiomyopathy is usually refractory to 
common medications and carries a very poor prognosis39. 
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2.2 Goals and scope of this study
This dissertation comprises two publications both addressing fundamental questions con-
cerning	HB.	The	first	project	aimed	to	further	examine	the	genetic	background	of	HB	and	
shed light onto molecular mechanisms driving this malignancy. The second project used a 
bioinformatic approach to identify new drug targets in high-risk HB and advance patient out-
come through novel treatment options. The scope of both projects is outlined in brief below.
2.2.1 The genomic landscape of hepatoblastoma and their progenies with HCC-like 
features
In order to gain further insights into the origin and the genetic background of HB, we conducted 
whole-exome sequencing of 15 HB samples and three samples of so-called transitional 
liver cell tumors (TLCT) as well as matched normal liver tissues. TLCT usually occur in 
older children, have a particularly poor outcome and are thought to be in a transitional state 
between HB and hepatocellular carcinoma (HCC) with distinct differences in morphology, 
immunophenotype and response to treatment40. 
We found HB to have a very simple genetic background with a surprisingly low mutation 
rate of only 2.9 mutations per tumor. Previously described CTNNB1 mutations were de-
tected in 12 of 15 HB samples. We found mutations in the nuclear factor (erythroid-derived 
2)-like 2 (NFE2L2) gene as the only other recurrent event with mutations in 2 out of 15 HB 
samples. 
TLCT had a much more complex genetic background with an average of 27.3 mutations 
per tumor, which roughly compares to the mutation frequency in adult HCC41, 42. All three 
TLCTs also had CTNNB1 mutations. Notably two TLCTs had mutations in the promoter of 
the telomerase reverse-transcriptase (TERT) gene. 
When we looked for chromosomal gains and losses we found the results to be largely in 
agreement	with	previous	findings.	HBs	showed	gains	at	chromosomes	1,	2,	8	and	20	and	
losses at chromosomes 4 and 11. TLCTs showed extreme chromosomal instability, which 
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might be explained by the deletion or mutation of the gate keeper genes RAD17, MSH6, 
and TP53. 
Other non-recurrent mutations included mostly genes involved in transcriptional regulation 
or chromatin organization. This partially explains why only so few mutations are needed in 
order to lead to an aggressive neoplasm like HB. Disrupting the transcriptional machinery 
or epigenetic chromatin regulation by mutations of key regulators has widespread conse-
quences on transcriptional programs and gene expression. 
To investigate whether the three recurrent mutations we found via whole-exome sequenc-
ing, namely CTNNB1, NFE2L2 and TERT, are also present in a larger cohort of patients 
we performed targeted sequencing of those genes in 33 additional primary tumors and cell 
lines. In the total cohort of now 51 cases we found CTNNB1, NFE2L2 and TERT mutations 
in 72.5%, 9.8% and 5.9% of cases, respectively. 
Interestingly TERT mutations exclusively occurred in TLCTs, making it a potential marker 
for the detections of high-risk patients. Mutations in the TERT promoter also lead to a signif-
icant overexpression of TERT in TLCTs compared to normal liver tissue. Notably, HBs also 
showed	a	significant,	however	slightly	less	pronounced	overexpression	of	TERT.  
Since we detected mutations of the transcription factor NFE2L2 in four HBs and one HB 
cell line, we set out to further explore the impact of those mutations on tumorigenesis. All 
mutations compromised the KEAP1/CUL3 binding site of NFE2L2, potentially interfering 
with KEAP1-mediated degradation of NFE2L2. By performing transcriptional reporter as-
says we found that most of the mutations lead to increased NFE2L2 transcriptional activity, 
insensitive to KEAP1-mediated inhibition. 
To determine whether NFE2L2 activation is also present in tumors without NFE2L2 mu-
tations, we measured expression levels of NQO1 in 47 primary tumor samples. NQO1 is 
a known NFE2L2 target gene, which has been shown to closely correlate with NFE2L2 
activity43. We found NQO1	 significantly	upregulated	 in	 liver	 tumor	samples	compared	 to	
normal liver tissues. More importantly, high NQO1	expression	was	significantly	associated	
with metastases, vascular invasion and the high-risk C2 subclass described above. In ac-
cordance with this, patients with high NQO1	expression	had	significantly	worse	outcomes	
in	terms	of	specific	survival.	
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While the exact molecular mechanism by which NFE2L2 activation contributes to HB-tum-
origenesis remains largely elusive, using NQO1 as a surrogate marker to measure NFE2L2 
activation	in	tumors	might	be	of	prognostic	significance	for	HB	patients.	
2.2.2	 Connectivity	map	identifies	HDAC	inhibition	as	a	treatment	option	of	high-risk	
hepatoblastoma
As described above, outcomes of HB patients have drastically improved with current treat-
ment regimens. However, there is still a subgroup of high-risk patients whose outcome 
remains poor. In addition, the aggressive chemotherapy regimen to which high-risk patients 
are submitted often result in severe late effects in the surviving children, as outlined in the 
first	part	of	this	introduction.	Therefore,	new	targeted	treatment	strategies	are	needed	to	im-
prove patient outcome and prevent long-term side effects from conventional chemotherapy.
Since	gene	expression	signatures	have	proven	useful	for	HB	risk	stratification	in	the	past	
we used expression data from 7 primary HBs and built a gene signature comprising the 
1,000 best discriminating genes between standard-risk C1 and high-risk C2 tumors as 
defined	by	the	16-gene	HB	classifier	described	above.	We	used	this	signature	as	input	for	
the Connectivity Map, a biomedical software tool, which is able to predict drugs potentially 
capable	of	inducing	or	reversing	gene	expression	profiles.	When	we	filtered	the	results	for	
drugs that could potentially reverse the high-risk C2 signature, the HDAC-inhibitor SAHA 
(vorinostat)	ranked	first	in	our	list.	
Histone	deacytelases	(HDACs)	are	epigenetic	chromatin	modifiers	that	are	able	to	inhibit	
transcription by promoting the formation of heterochromatin. This often leads to aberrant 
silencing of tumor suppressor genes and contributes to the development of various tu-
mor entities44. Since high HDAC expression levels are a common feature in many cancers 
and	have	also	been	suggested	as	a	positive	predictor	for	the	efficacy	of	HDAC	inhibition	
(HDACi)45, 46, we examined HDAC expression levels in 35 primary HBs and cell lines and 
compared them to the expression in normal liver tissue. HDAC 1, 2 and 4 were generally 
overexpressed	in	tumor	tissue	and	cell	lines.	Interestingly,	we	found	a	significant	correla-
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tion between high expression levels of HDAC 1 and 2 and tumors exhibiting the high-risk 
C2 signature. Notably, overexpression of HDAC 1 and 2 have been described as a marker 
associated with poor prognosis in other solid tumors47, 48.
To evaluate HDACi as a potential treatment option for HB we tested the effect of two HDAC 
inhibitors on liver tumor cell lines. The pan HDAC inhibitor SAHA was able to potently re-
duce cell viability in a dose dependent manner, while the subclass HDAC inhibitor MC1568 
had only minor effects on cells. When we investigated how HDAC inhibitors conveyed 
growth inhibition, we found that SAHA treatment led to strong induction of apoptosis in 
HB cells, while cell cycle progression appeared to be unaffected. Further analysis showed 
a strong re-expression of hedgehog-interacting protein (HHIP), secreted frizzeled-related 
protein 1 (SFRP1) and insulin-like growth factor-binding protein 3 (IGFBP3) upon HDACi. 
As mentioned above, those three tumor suppressor genes are known to be epigenetically 
silenced	in	HB.	These	findings	suggest	a	functional	connection	between	re-expression	of	
HB	specific	tumor	suppressor	genes	and	the	apoptotic	effect	of	HDACi.	
Since the Connectivity Map predicted that HDACi might be able to reverse the high-risk C2 
signature we analyzed gene expression patterns in cell lines exhibiting the adverse C2 ex-
pression	profile	before	and	after	HDACi.	In	agreement	with	the	Connectivity	Map	analysis	
we found a major shift in gene expression towards the standard-risk C1 signature in HB 
cells treated with HDAC inhibitors. As standard-risk tumors are more susceptible to con-
ventional chemotherapy compared to high-risk tumors, we hypothesized that HDACi might 
sensitize HB cells to chemotherapy, especially to cisplatin. 
In order to investigate this hypothesis we combined HDAC inhibitors with cisplatin and com-
pared the effect on HB cells with the effect of the current high-risk chemotherapy regimen, 
which combines cisplatin and doxorubicin. We detected strong synergies between HDAC 
inhibitors and cisplatin at most concentrations, while synergies between cisplatin and doxo-
rubicin were detected for only a few concentrations. Notably, we found combinations of cis-
platin and SAHA to be equally and at some concentrations even more effective in reducing 
cell viability when compared to combinations between cisplatin and doxorubicin. These 
findings	indicate	that	HDACi	is	in	fact	capable	of	sensitizing	HB	cells	to	cisplatin.
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While further studies are needed to evaluate HDACi as a targeted treatment option in vivo, 
it holds the potential to replace cardiotoxic anthracyclines in high-risk treatment protocols 
and reduce the cumulative dose of oto- and nephrotoxic cisplatin due to its synergistic ef-
fects,	without	compromising	treatment	efficacy.	
2.3 Contribution
The doctoral candidate Alexander Beck contributed to the publication “The genomic land-
scape of hepatoblastoma and their progenies with HCC-like features” by conducting ex-
periments	concerned	with	 the	 identification	and	validation	of	mutations	 in	additional	pri-
mary tumor samples that were not submitted to whole-exome sequencing. Furthermore, 
he	was	involved	in	the	functional	characterization	of	candidate	genes	initially	identified	by	
whole-exome sequencing. Mr. Beck also contributed in the drafting of the manuscript. 
For	the	publication	“Connectivity	map	identifies	HDAC	inhibition	as	a	treatment	option	of	
high-risk hepatoblastoma” the doctoral candidate conducted the bioinformatic analyses that 
lead	to	the	identification	of	several	compounds	for	the	potential	treatment	of	high-risk	HB.	
He planned and performed the vast majority of experiments and carried out the statistical 
analysis	of	clinical	data.	He	also	wrote	the	manuscript	and	created	all	of	the	figures.	
11
3. Summaries
3.1 Summary in English
Hepatoblastoma (HB) is a rare pediatric tumor, almost exclusively occurring in children 
under	the	age	of	five	years.	This	embryonic	malignancy	is	thought	to	arise	from	early	he-
patocyte precursor cells unable to reach their terminal differentiation due to genetic and 
epigenetic events disturbing normal organ development. While some of those events are 
well documented the exact mechanisms driving HB tumorigenesis remain largely unknown. 
Over the last few decades several clinical trials were able to identify promising treatment 
regimens for HB patients. Common treatment protocols involve neoadjuvant chemotherapy 
followed by surgical resection and adjuvant chemotherapy. Standard-risk patients achieve 
excellent outcomes with this treatment, with a three-year overall survival rate of 95%. Un-
fortunately, the outcome for high-risk patients presenting with vast tumor extensions, dis-
tant metastases and vascular invasion remains poor. In addition, the cytotoxic agents uti-
lized in HB treatment protocols can cause severe adverse effects including irreversible and 
potentially life threatening organ damage. 
The research presented in this dissertation attempts to elucidate the genetic events in HB 
and the molecular mechanisms driving this malignancy. It also aims at identifying novel 
drug targets especially in high-risk patients with the goal of improving patient outcomes and 
reducing side effects from conventional chemotherapeutic agents. 
Achieving those objectives involved whole-exome sequencing of primary HB samples, 
which revealed a very simple genetic background of only 2.9 mutations per tumor. We 
found recurring mutations in CTNNB1, NFE2L2 and TERT, the latter of which were ex-
clusively present in so-called transitional liver cell tumors (TLCT) and could represent a 
characterizing marker for this rare subgroup of HB. Mutations in the transcription factor 
NFE2L2 rendered it insensitive to proteasomal degradation, leading to increased transcrip-
tional activity. This increased activity was also detected in HBs with no NFE2L2 mutations 
as assessed by the expression of the NFE2L2 target gene NQO1, an established surrogate 
marker of NFE2LE activity. Overexpression of NQO1	 in	HB	was	significantly	associated	
with metastasis, vascular invasion, the adverse prognostic C2 gene signature and poor 
outcome, making NQO1	a	potential	biomarker	for	risk-stratification.	
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In	order	to	find	new	targeted	therapies	for	high-risk	HB	we	used	a	bioinformatic	approach	
and	identified	HDAC	inhibitors	as	a	promising	therapy	option.	Subsequent	expression	anal-
ysis showed overexpression of several HDAC subclasses in primary tumors and HB cell 
lines,	which	has	been	suggested	to	be	predictive	for	the	efficacy	of	HDAC	inhibition.	Treat-
ment of HB cells with HDAC inhibitors resulted in potent growth inhibition, strong induction 
of apoptosis and re-expression epigenetically silenced tumor suppressor genes. HDAC 
inhibition also shifted the transcriptional program in HB cells from a high-risk expression 
profile	to	a	more	standard-risk	expression	signature.	Combination	of	HDAC	inhibitors	and	
cisplatin	showed	strong	synergies,	which	lead	to	efficacious	reduction	of	HB	cell	viability,	
even	at	very	low	cisplatin	doses.	Our	findings	suggest	HDAC	inhibition	as	a	novel	treatment	
option for high-risk HB that holds the potential to reduce doses of conventional chemother-
apeutic	agents	without	compromising	efficacy.	
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3.1 Summary in German
Das Hepatoblastom (HB) ist ein seltener pädiatrischer Tumor, der fast ausschließlich bei 
Kindern im Alter von unter fünf Jahren auftritt. Man nimmt an, dass dieser embryonale Tu-
mor aus Hepatozyten-Vorläufern entsteht, die sich nicht richtig differenzieren können, da 
genetische und epigenetische Ereignisse die normale Organentwicklung stören. Obwohl 
einige dieser Ereignisse gut dokumentiert sind, bleiben die genauen Mechanismen, welche 
die Tumorgenese des HB vorantreiben weitgehend unbekannt. 
Während der letzten Jahrzehnte gelang es durch zahlreiche klinische Studien vielverspre-
chende	Behandlungsmöglichkeiten	für	HB	Patienten	zu	identifizieren.	Herkömmliche	Be-
handlungsprotokolle beinhalten eine neoadjuvante Chemotherapie, gefolgt von einer chiru-
rgischen Resektion und einer adjuvanten Chemotherapie. Mit diesem Therapiekonzept 
erzielt man bei Standardrisiko-Patienten hervorragende Erfolge mit 3-Jahres-Überleben-
sraten von 95%. Leider ist das Outcome von Hochrisiko-Patienten mit ausgedehntem Tu-
morbefall,	Metastasen	und	Gefäßinfiltration	nach	wie	vor	schlecht.	Hinzukommt,	dass	die	
zytotoxischen Substanzen, die in der HB Therapie zum Einsatz kommen, schwere Neben-
wirkungen verursachen können, einschließlich irreversibler und potential lebensbedrohli-
cher Organschäden. 
Die vorgelegte Arbeit zielt darauf ab, genetische Veränderungen im HB eingehender zu 
untersuchen und molekulare Mechanismen aufzudecken, welche zur Tumorentstehung 
beitragen.	 Sie	 beschäftigt	 sich	 auch	 mit	 der	 Identifizierung	 von	 gezielten	
Behandlungsmöglichkeiten insbesondere für Hoch-Risikopatienten mit dem Ziel, das 
Outcome dieser Patientengruppe zu verbessern und Nebenwirkungen durch konventionelle 
Chemotherapeutika zu reduzieren. 
Die Exom-Sequenzierung von HB Tumorgewebe offenbarte einen erstaunlich simplen 
genetischen Hintergrund mit durchschnittlich 2,9 Mutationen pro Tumor. Wir fanden 
wiederkehrende Mutationen in den Genen CTNNB1, NFE2L2 und TERT, wobei letztere 
ausschließlich in sogenannten transitionalen Leberzelltumoren (TLCT) auftraten und 
einen charakteristischen Marker für diese seltene Untergruppe des HB darstellen könnten. 
Mutationen im Transkriptionsfaktor NFE2L2 beeinträchtigten dessen proteosomalen Abbau 
und erhöhten so dessen transkriptionelle Aktivität. Diese erhöhte Aktivität war auch in 
Tumoren nachweisbar, die keine NFE2L2 Mutation aufwiesen und konnte über das NFE2L2 
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Zielgen NQO1 nachgewiesen werden, dessen Expression ein etablierter Surrogatmarker 
der NFE2L2 Aktivität ist. Die Überexpression von NQO1 in HB Gewebe war zudem 
signifikant	mit	 dem	Auftreten	von	Metastasen,	Gefäßinfiltration	und	der	ungünstigen	C2	
Gensignatur assoziiert. Entsprechend war eine hohe NQO1 Expression auch mit einem 
schlechten Patienten-Outcome verbunden, weshalb NQO1 einen potentiellen Biomarker 
zur	Risikostratifizierung	darstellt.	
Um	neue	gezielte	Behandlungsmöglichkeiten	für	Hochrisiko-HB-Patienten	zu	finden,	ver-
folgten	wir	einen	bioinformatischen	Ansatz	und	identifizierten	so	HDAC	Inhibitoren	als	eine	
vielversprechende Therapieoption. Eine darauffolgende Expressionsanalyse zeigte die 
Überexpression von mehreren HDAC-Untergruppen in primärem HB Gewebe und Tumor-
zelllinien. Die Überexpression von HDACs gilt als prädiktiver Marker für die Wirksamkeit 
von HDAC Inhibitoren. Die Behandlung von HB Zellen mit solchen HDAC Inhibitoren führte 
zu einer wirkungsvollen Wachstumshemmung, einer starken Induktion von Apoptose und 
der Reaktivierung von epigenetisch stillgelegten Tumor-Suppressor-Genen. Die HDAC In-
hibition führte außerdem zu einer Verschiebung des Transkriptionsprogramms in HB Zel-
len	von	einem	Hochrisiko-Expressions-Profil	zu	einer	eher	dem	Standardrisiko	entsprech-
enden Expressions-Signatur. Die Kombination von HDAC Inhibitoren und Cisplatin zeigte 
starke Synergien, welche selbst bei sehr niedriger Cisplatin-Dosierung zu einer wirksamen 
Reduktion der HB-Zellviabilität führten. Unsere Ergebnisse sprechen für den Einsatz von 
HDAC Inhibitoren als neuartige Therapieoption bei HB-Patienten der Hochrisikogruppe mit 
dem Potential die Gesamtdosis konventioneller Chemotherapeutika zu reduzieren, ohne 
die Wirksamkeit der Therapie zu gefährden. 
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Background & Aims: Hepatoblastoma (HB) is the most common
childhood liver cancer and occasionally presents with histological
and clinical features reminiscent of hepatocellular carcinoma
(HCC). Identification of molecular mechanisms that drive the
neoplastic continuation towards more aggressive HCC pheno-
types may help to guide the new stage of targeted therapies.
Methods: We performed comprehensive studies on genetic and
chromosomal alterations as well as candidate gene function
and their clinical relevance.
Results: Whole-exome sequencing identified HB as a genetically
very simple tumour (2.9 mutations per tumour) with recurrent
mutations in ß-catenin (CTNNB1) (12/15 cases) and the transcrip-
tion factor NFE2L2 (2/15 cases). Their HCC-like progenies share the
common CTNNB1 mutation, but additionally exhibit a signifi-
cantly increased mutation number and chromosomal instability
due to deletions of the genome guardians RAD17 and TP53, accom-
panied by telomerase reverse-transcriptase (TERT) promoter
mutations. Targeted genotyping of 33 primary tumours and cell
lines revealed CTNNB1, NFE2L2, and TERT mutations in 72.5%,
9.8%, and 5.9% of cases, respectively. All NFE2L2 mutations
affected residues of the NFE2L2 protein that are recognized by
the KEAP1/CUL3 complex for proteasomal degradation. Conse-
quently, cells transfected with mutant NFE2L2 were insensitive
to KEAP1-mediated downregulation of NFE2L2 signalling. Clini-
cally, overexpression of the NFE2L2 target gene NQO1 in tumours
was significantly associated with metastasis, vascular invasion,
the adverse prognostic C2 gene signature, as well as poor outcome.
Conclusions: Our study demonstrates the importance of CTNNB1
mutations and NFE2L2-KEAP1 pathway activation in HB develop-
ment and defines loss of genomic stability and TERT promoter
mutations as prominent characteristics of aggressive HB with
HCC features.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Hepatoblastoma (HB) is a highly malignant liver tumour, arising
in children under the age of three years, with a histology that
resembles various stages of the developing liver comprising epi-
thelial phenotypes (less differentiated embryonal and differenti-
ated foetal) and mesenchymal elements such as immature
fibrous tissue or osteoid [1]. Occasionally, an aggressive subtype
of HB presents in children >5 years of age with clinical and histo-
pathological features reminiscent of hepatocellular carcinoma
(HCC) [2]. This so-called transitional liver cell tumour (TLCT)
has been suggested to indicate a neoplastic continuation along
an ontogenetic differentiation pathway from HB to HCC [2].
Based on its early manifestation it is generally assumed that
HB displays a relatively normal genomic background, which is
reflected by the detection of only a few cytogenetic and genetic
alterations [3]. So far, mutation of ß-catenin (CTNNB1), the key
molecule of Wnt signalling, represents the only recurrent alter-
ation found in about two thirds of HB patients, mainly hitting
exon 3 either by point mutation or deletion [4]. This leads to
the disruption of phosphorylation sites, which are needed to
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tag CTNNB1 for proteasomal degradation by a destruction com-
plex consisting of the adenomatous polyposis coli (APC) protein,
AXIN, glycogen synthase kinase 3, and casein kinase 1. Consis-
tently, somatic mutations of APC as well as AXIN1 and AXIN2 have
been found in HB, although at a very low frequency [5,6]. Of note,
genetic lesions in CTNNB1, AXIN1, and AXIN2 are similarly
observed in adult HCC [6,7]. These data clearly underscore the
significance of activated Wnt signalling in the genesis of liver
cancer, both in very young children and adults [8].
Based on recent transcriptional data, HB can be distinguished
into two distinct groups: the so-called C1 subclass that recapitu-
lates liver features at late stages of intrauterine life with a mostly
foetal histotype and the expression of markers of mature hepato-
cytes, and the C2 subclass that resembles earlier stages of liver
development with a predominantly embryonal histotype and
the expression of markers of hepatic progenitor cells, such as cyto-
keratin 19 and EpCAM [9]. Most importantly, a specific 16-gene
signature has been deduced from these profiling experiments that
predicts outcome of HB patients better than classical criteria, such
as tumour stage by pretreatment extent of disease (PRETEXT),
vascular invasion, and extrahepatic metastases. Besides this char-
acteristic expression profile, HB displays a general overexpression
of several developmental genes, including the imprinted genes
IGF2 [10] and DLK1 [9] as well as genes involved in the hedgehog
pathway [11]. Although the cause for the upregulation of these
genes is still enigmatic, epigenetic mechanisms such as loss of
imprinting and promoter hypermethylation have been empha-
sized [3].
The aim of this study was to further our understanding of the
genetic basis of HB and to identify molecular mechanisms that
drive a neoplastic continuation towards HCC by applying whole-
exome sequencing.
Materials and methods
Patients and materials
A total of 47 liver tumour specimens were obtained from paediatric patients
undergoing surgical resection in our department. Written informed consent
was obtained from each patient and the study protocol was approved by the local
authorities. Furthermore, we used the four human HB cell lines HepT1, HepT3
(both provided by Dr. T. Pietsch), HuH6 (Japanese Collection of Research Biore-
sources, Osaka, Japan), and HepG2 (ATCC, Manassas, VA, USA), as well as the
HEK293T cell line (ATCC). Tumour samples and HB cell lines were assigned to
C1 and C2 subtypes using the 16-gene classifier as reported previously [9].
Human NFE2L2 cDNAs (wild type and mutant forms) were subcloned into the
pEGFP-N1 vector (Clontech, Mountain View, CA) by polymerase chain reaction
(PCR); cloning and sequence was verified by Sanger sequencing. The pFLAG-
KEAP1 expression construct and the pNQO1-ARE luciferase reporter vectors have
been described previously [12,13].
Exome sequencing
All tumour samples were clinically and pathologically well-characterized and
macro-dissected to enrich for neoplastic cellularity. Genomic DNA of 18 fresh-
frozen tumour specimens and matched healthy liver tissues was extracted with
the DNeasy blood and tissue Kit (Qiagen, Hilden, Germany). Quality was checked
by electrophoresis in a 1% agarose gel and quantitatively measured using the
NanoDrop 1000 instrument (Thermo Scientific, Wilmington, DE, USA).
Exomes were enriched in solution with SureSelect XT Human All Exon 50 Mb
kits (Agilent Technologies, Santa Clara, CA, USA) and sequenced as 100 bp paired-
end runs on a HiSeq2500 system (Illumina, San Diego, CA, USA) generating 7–
14 Gb of sequence and an average read depth between 87 and 172 on target
regions. More than 90% of the target regions were covered 20 times or more. Bur-
rows-Wheeler Aligner (BWA v 0.5.9) with standard parameters was used for read
alignment against the human genome assembly hg19 (GRCh37). We performed
single-nucleotide variant and small insertion and deletion (indel) calling for the
regions targeted by the exome enrichment kit using SAMtools (v 0.1.18). Large
indels were called with Pindel (v 0.2.4t) and copy number variations (CNV) were
determined using the R package ExomeDepth (v 0.9.7). Allelic imbalances were
determined by calculating the fraction of reads carrying the mutation in the
tumour sequences at genomic positions where heterozygous SNVs were present
in the control tissue.
To discover putative somatic variants, we retrieved only those variants of a
tumour that were not found in the corresponding control tissue. To reduce the
number of false positives, we filtered out variants that were already present in
3500 ‘‘in house’’ control exomes (patients with unrelated diseases and healthy
controls from other projects) or had variant quality of less than 30. Furthermore,
the variants were filtered according to several quality criteria using the SAMtools
varFilter script. We used default parameters, with the exception of the maximum
read depth (-D) and the minimum p value for base quality bias (-2), which we set
to 9999 and 1e-400, respectively. Moreover, we applied a custom script that
marked all variants where the median base quality of adjacent bases was low,
because these variants are often sequencing artefacts. We then manually investi-
gated the raw read data of the remaining variants using the Integrative Genomics
Viewer (IGV v2.3.19).
Sanger sequencing
Sequence verification was carried out by PCR amplification of candidate exons
using High Fidelity Taq polymerase (Thermo Scientific, Schwerte, Germany) and
subsequent Sanger sequencing of ExoSap-IT (Affymetrix, Santa Clara, CA, USA)
purified amplicons. PCR conditions for detecting mutations in exon 2 of the NFE2L2
gene (primers NRF2-EX2-F and NRF2-EX2-R), point mutations (primers BCAT-1 and
BCAT-2) or deletions (primers BCAT-3 and BCAT-4) in exon 3 of the CTNNB1 gene as
well as TERT promoter mutations have been described previously [4,14,15].
Sequencing was done on an ABI 3730 capillary sequencer in the LMU sequencing
facility using the ABI BigDye Terminator kit (Applied Biosystems, Foster City, CA).
Sequence analysis was performed using the Staden Package 2.0 program.
Real-time PCR
RNA extraction and purification, cDNA synthesis, PCR amplifications and quanti-
zation of gene expression were performed as described before [11] using the fol-
lowing primer pairs: TERT, CACGGAGACCACGTTTCAAA, GCACCCTCTTCA
AGTGCTGTC; NQO1, GCTGCCATGTATGACAAAGGAC, CCGGTGGATCCCTTGCAGA;
TBP, GCCCGAAACGCCGAATAT, CCGTGGTTCGTGGCTCTCT.
NQO1-antioxidant response element (ARE) reporter assay
Cells were seeded in 12-well plates the day before transfection. Cells were then
transfected with 200 ng of the reporter plasmid pNQO1-ARE-Luc, 200 ng expres-
sion constructs (pEGFP-N1, pEGFP-WT, pEGFP-L30P, pEGFP-R34P, pEGFP-R34G,
or pEGFP-T80A), 200 ng pFLAG-KEAP1, and 10 ng of the reference plasmid pRL-
CMV (Promega, Madison, Wisconsin, USA) using the XtremeGENE HP transfection
reagent (Roche Diagnostics) as recommended. 48 h after transfection, cells were
lysed and reporter gene activity was determined using the Dual-Glo Luciferase
Reporter Assay System (Promega). Firefly luciferase activity was normalized to
Renilla luciferase activity. All reporter assay experiments were repeated four
times and transfections done in duplicate.
NFE2L2 localization analyses
Cells were seeded onto 18 mm coverslips (Thermo Scientific, Braunschweig, Ger-
many) the day before transfection and then transfected with the respective GFP-
tagged NFE2L2 expression constructs using XtremeGENE HP (Roche Diagnostics).
After 48 h cells were washed with PBS and fixed with 3% paraformaldehyde. Pro-
cessed coverslips were counterstained with Vectashield containing 4,6-diamidi-
no-2-pheylindole (Vector Laboratories Inc., Burlingame, CA, USA) and mounted
onto glass slides. Images were acquired using the Zeiss Axiovert 135 Microscope
(Zeiss, Jena, Germany).
Statistical analyses
Data were expressed as means ± standard deviation (SD) or standard error of the
mean (SEM) and statistically subjected to Student’s unpaired t test and Spear-
man’s rank correlation test. Kaplan-Meier estimates of specific survival time in
the various groups were compared using the log-rank Mantel-Cox test. A level
of p <0.05 was considered to be significant, p <0.01 highly significant.
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Functional annotation of mutated genes was performed using the DAVID
Bioinformatics Resources v6.7 (National Cancer Institute, Frederick, MD) by com-
puting gene-ontology statistics against the whole human genome database.
Results
Hepatoblastoma harbours only few somatic mutations
To better understand the genetic basis of childhood liver cancer,
we performed whole-exome sequencing on a discovery cohort of
15 HB and three TLCT as well as matched normal liver tissues.
Using stringent criteria, we identified a total of 125 somatic
mutations (Supplementary Table 1). In HB, the overall mutation
rate was very low with only 2.9 (range 1 to 7) variants per
tumour genome (Fig. 1A), with a preponderance of deletions
(Fig. 1B). Interestingly, six tumours showed only one somatic
mutation, suggesting that acquisition of very few somatic muta-
tions might be sufficient to drive tumour development in the
liver. In their HCC-like progenies, the mean sequence variation
rate increased to 27.3 (range 11 to 48) per tumour genome, indi-
cating an almost comparable frequency to adult HCC that ranges
from 35 to 66 [16–18]. The distribution of somatic substitutions
revealed the predominance of C:G to T:A transitions in HB and
TLCT (Fig. 1B), which is consistent with data on adult HCC
tumours that develop on non-cirrhotic livers [17] and might be
explained by spontaneous deamination [19] and/or the high GC
content of coding exons [20]. Since we found no age-dependency
in HB and TLCT by plotting the mutation number against the
onset of the disease (Fig. 1C), other factors than the longer expo-
sure time to genotoxic influences could have contributed to the
more advanced genetic level of TLCT.
Increased chromosomal instability in hepatoblastoma with HCC
features
Recent studies have shown that exome sequencing can be suc-
cessfully used to detect allelic imbalances and copy number vari-
ations [21], thereby enabling us to resolve chromosomal gains,
losses, and copy-neutral allelic imbalances (Fig. 2A and B, Supple-
mentary Table 2). Frequent gains were found at chromosome 2
(11/18), 1q (8/18), 20 (6/18), 6p (4/18), 8q (4/18), 12 (4/18),
and 17 (4/18), whereas recurrent losses and/or copy-neutral alle-
lic imbalances occurred at chromosome 11p (6/18) and 4q (5/18).
These results are comparable to earlier work, which also detected
far more gains than losses, especially on chromosomes 2 (44%),
1q (41%), 20 (24%), and 8q, the latter two being predictive for
poor outcome [22]. Of note, copy-neutral allelic imbalances on
the distal part of chromosome 11p presumably reflecting loss of
heterozygosity at the IGF2/H19 locus were specific for HB,
whereas TLCT showed deletions of this region.
Interestingly, the mutation rate correlated with the number of
chromosomal alterations (r = 0.7155; p = 0.0008). This was espe-
cially true for the two cases TLCT-227 and TLCT-291, in which we
found the highest mutation rate of the discovery set, accompa-
nied by an extreme chromosomal instability (Fig. 2B). Accord-
ingly, TLCT-227 harbours a small deletion on chromosome 5
encompassing the locus of the RAD17 gene (Fig. 2C), which is
known to be essential for the maintenance of chromosomal
stability [23]. In addition, we found a c.3991C>T mutation in
the MSH6 gene giving rise to a premature stop codon (Supple-
mentary Table 1). Although MSH6 is considered to exclusively
play a role in microsatellite instability, a first implication in chro-
mosomal instability has recently been demonstrated in sporadic
colorectal cancer [24]. In TLCT-291 we detected a small deletion
on chromosome 17 at the locus of TP53 (Fig. 2C), a tumour
suppressor involved in chromothripsis [25]. These findings
suggest that mutations in genes involved in chromosomal stabil-
ity might be an important mechanism to drive malignant liver
cells towards a more aggressive HCC-like phenotype.
Transcriptional regulators are frequently mutated in childhood liver
cancer
In order to identify molecular mechanisms that are frequently hit
by mutations in childhood liver cancer, we performed functional
annotation of the mutated genes, using the DAVID database (Sup-
plementary Table 3). The main biological processes detected in the
15 HB were transcription (30% of mutated genes), chromatin orga-
nization (20%), and chromosome organization (20%). Accordingly,
the top-scoring cellular component was the nucleoplasm (13.3%).
The most prominent candidate genes code for histone H3.1
(HIST1H3C), histone deacetylase 4 (HDAC4), lysine-specific
demethylase 5C (KDM5C), lysine-specific methyltransferase 2C
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Fig. 1. Exome sequencing of paediatric liver tumours. (A) Distribution of
somatic mutations as well as (B) frequency of insertions/deletions (indels) and
nucleotide substitutions identified in 15 hepatoblastoma (HB) and 3 transitional
liver cell tumour (TLCT) cases. (C) The age of disease onset of HB (left) and TLCT
(right) cases was plotted against the number of somatic mutations and
Spearman’s rank correlation was performed, with the linear regression depicted
in orange. (This figure appears in colour on the web.)
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(KMT2C), two co-repressors interacting with histone deacetylases
(CIR1, BCORL1), one co-repressor binding polycomb repressive
complex 2 (ASXL2), one E3 ubiquitin protein ligase (MYCBP2), as
well as one transcription factor (NFE2L2). By looking into the TLCT
candidate genes, we again found transcription and its regulation
being the main biological processes. Important mutated genes
comprise the co-repressor GON4L, two co-activators (PRIC285,
CCDC101), another E3 ubiquitin protein ligase (HUWE1), as well
as several transcription factors (MYC, GATA6, HOXD11, PRDM10,
NFX1). These data clearly indicate that deregulation of the tran-
scription machinery is an important step in liver cancer
development.
Activation of Wnt signalling is the key event in liver tumourigenesis
Alteration of CTNNB1 was the most prominent feature in paediat-
ric liver tumours affected by either non-silent mutations (4 cases)
or deletions (11 cases) of exon 3 (Supplementary Table 1).
Intriguingly, three HB showed mutations in CTNNB1 as the sole
event, without any further genetic or chromosomal alteration.
Additionally, we found chromosomal loss of the APC locus
(Fig. 2A) as the second hit to the already known inherited
c.3809_3810insC frame-shift mutation in the APC gene (Supple-
mentary Table 1) in a 9-month-old female with familial ade-
nomatous polyposis syndrome. These data clearly indicate that
activation of the Wnt pathway is the key driver of tumourigenesis
in the liver. However, two HB that lack mutations in any of the
Wnt-associated genes (Fig. 2A) suggested that other molecular
mechanism must exist. Indeed, we found a 506 bp deletion in
the putative tumour suppressor gene KMT2C as the only alter-
ation in HB-744 (Supplementary Table 1). Interestingly, KMT2C
(alias MLL3) was recently identified to be mutated in a variety
of cancers, including 5.4% of HCC and 14.8% of cholangiocarci-
noma cases [26,27].
Promoter mutation of TERT exclusively occurs in transitional liver
cell tumours
Previous studies have shown that HCC and their preneoplastic
lesions carry specific somatic mutations in the promoter region
of the telomerase reverse-transcriptase (TERT) gene, which could
lead to transcriptional upregulation of TERT [15]. By visual
inspection of the respective region that is not systematically cov-
ered by exome data analysis tools, we found TERT promoter
mutations in two cases diagnosed as TLCT (Fig. 2B). Screening
of a validation cohort of 33 primary tumours and cell lines by
conventional Sanger sequencing revealed only one additional
TERT promoter mutation, namely in the HepG2 cell line
(Figs. 2D and 3A). Although HepG2 cells have recently been
reclassified based on the original resection specimen as epithelial
HB [28], it should be at least envisioned that it might be a TLCT
due to the advanced age of the patient (15-year-old boy) and
the fact that HB exclusively occurs in children under the age of
five years [3]. Strikingly, our results resemble recent findings in
adult liver tumours, which showed that hepatocellular adenoma
with HCC foci, as also evident in TLCT (Fig. 2E), as well as HCC,
were mutated in 44% and 59% of all cases, respectively [15]. By
looking into mRNA expression we found significantly increased
TERT levels in HB and TLCT compared to normal liver tissues
(Fig. 2F). Although there was a trend towards TERT upregulation
in TERT mutated cases and cell lines, no significant difference
between HB and TLCT was found. Taken together, these data sug-
gest that the TERT promoter mutation is a selective phenomenon
of advanced HB with HCC-like features, thereby providing an
excellent marker for the detection of high-risk patients.
Recurrent NFE2L2 mutations in hepatoblastoma
Besides CTNNB1 and TERT we identified missense mutations in
the nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) gene as
another recurrent event, which was affected in two HB cases
(Supplementary Table 1). Targeted sequencing of our validation
cohort identified missense mutations in two other HB cases and
in the HepT1 cell line (Supplementary Fig. 1A), altogether in
9.8% of cases (Fig. 3A). Interestingly, the five NFE2L2 mutations
were found in cases harbouring CTNNB1 mutations (72.5% of all
cases), a coincidence already described for adult HCC [17]. NFE2L2
mutations were located either in or adjacent to the DLG and ETGE
motifs (Supplementary Fig. 1B), which have been described to be
essential for binding of the KEAP1/CUL3 complex that mediates
ubiquitination and proteasomal degradation of NFE2L2 [14]. In
order to determine whether the identified NFE2L2 mutations lead
to NRF2 transcriptional activity that is insensitive to KEAP1-med-
iated degradation, we cloned the wild type and the four mutated
forms of NFE2L2 (L30P, R34P, R34G, and T80A) into a GFP-tagged
vector and ectopically expressed them in the presence or absence
of KEAP1 in HEK293T cells that are known to exhibit low basal
levels of NFE2L2-dependent transactivation [13]. Using a firefly
luciferase reporter with an ARE binding sites as readout for
NFE2L2 transcriptional activity [13], we found that both wild
type and mutant NFE2L2 strongly increased reporter activity,
which was more pronounced for the mutant forms (Fig. 3B).
Co-transfection of KEAP1 resulted in a significant decrease in
reporter activity in wild type NFE2L2 and R34P transfected cells,
whereas in cells transfected with the mutated forms L30P,
R34G, and T80A this reduction was completely prevented. In line
with this, the latter three mutated forms accumulated exclusively
in the nucleus indicative for transcriptional activity, while the
R34P mutant as well as wild type NFE2L2 were found both in
the cytoplasm and the nucleus (Fig. 3C). Accordingly, the same
sets of experiments were performed in the HB cell line HuH6,
which has a comparably low NFE2L2-dependent transactivation
as HEK293T, showing identical results (Supplementary Fig. 1C
and D). HepG2 cells that have already a high endogenous NFE2L2
transcriptional activity followed the same trend, but without
reaching statistical significance. These data clearly demonstrate
that NFE2L2 mutations found in HB result in a high NFE2L2 tran-
scriptional activity by interfering with KEAP1-mediated
degradation.
Upregulation of the NFE2L2 target gene NQO1 is associated with
poor outcome
In order to see whether transcriptional deregulation of NFE2L2
signalling is a common phenomenon in paediatric liver cancers,
we determined the expression level of the target gene NQO1 in
our cohort of 43 HB and 4 TLCT primary tumours. NQO1 was cho-
sen because it has been described as a reliable NFE2L2 target in
NFE2L2-activated cancers [13,14] and outcompeted several other
target genes known from non-malignant conditions by most clo-
sely reflecting the NFE2L2 mutational status of our HB cases (Sup-
plementary Fig. 2A) and being transcriptionally activated up to
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Fig. 3. Mutational status and functional relevance of NFE2L2 in hepatoblastoma. (A) Clinicopathological characteristics and the mutational status of the CTNNB1, APC,
and NFE2L2 genes as well as the TERT promoter region are color-coded and depicted in rows for each tumour of our cohort of 43 hepatoblastoma (HB) and 4 transitional
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JOURNAL OF HEPATOLOGY
Journal of Hepatology 2014 vol. 61 j 1312–1320 1317
22
Author's personal copy
25-fold in HB (Supplementary Fig. 2B) when looking into previ-
ously published microarray data [9]. We found a striking upreg-
ulation of NQO1 in the tumour tissues compared to normal
livers (Fig. 3D), with no main differences between HB and TLCT.
Interestingly, three tumours harbouring NFE2L2 mutation exhib-
ited the highest NQO1 expression. Mutations of the genes KEAP1
and CUL3, which have been described to be alternatively mutated
in NFE2L2-activated cancers [13,29], were ruled out by targeted
sequencing of high NQO1 expressing tumours that lack NFE2L2
mutations, thereby suggesting alternative genetic and/or epige-
netic mechanisms that drive activation of NFE2L2 signalling in
paediatric liver cancers.
By correlating NQO1 expression with clinicopathological fea-
tures such as gender, onset of disease, histology, multifocal
growth, outcome, and the high-risk characteristics vascular
invasion (main portal vein, vena cava or three hepatic veins),
intra-abdominal extrahepatic extension, metastatic disease,
tumour in all liver sections (PRETEXT-IV), or alpha-fetoprotein
at diagnosis less than 100 ng/ml [30], we found that NQO1 was
significantly increased in metastatic and vessel invasive tumours
(Fig. 3E). Interestingly, the aggressive C2 molecular subtype,
assigned by the prognostic 16-gene signature [9], was also signif-
icantly associated with high NQO1 expression. In line with this,
specific survival of patients with high NQO1 expression was
significantly worse compared to low expressers (Fig. 3F). These
data suggest that NFE2L2 activation might be of prognostic
significance for HB patients.
Discussion
Our exome sequencing study provides the first comprehensive
catalogue of genetic alterations in paediatric liver tumours and
adds to the growing list of genomic landscapes clearly indicating
that childhood cancers do not require as many genetic alterations
as typical adult cancers. HB displays a genetically very simple
tumour with one of the lowest mutation rates ever reported for
any malignancy [31]. Contrarily, TLCT exhibited a mutation rate
merely comparable to the frequency found in adult HCC [16–
18], thereby implying a more advanced genetic level that could
be explained by the higher degree of so-called passenger muta-
tions in this tumour type. It is well established that passenger
mutations provide an evolutionary clock that precisely records
the number of DNA replications a cell has made [19]. However,
we found no positive correlation between increased patients’
age and mutation number, a phenomenon that has been described
for medulloblastoma [32] and neuroblastoma [33]. Instead, muta-
tions in the gate keeper genes RAD17, MSH6, and TP53 that ensure
chromosomal stability might have contributed to the higher
mutation rates in TLCT, which is also known from HCC, prostate
adenocarcinoma, and medulloblastoma [25,26,34]. Thus, it might
be assumed that TLCT is a progeny of HB that has lost its genomic
integrity, rather than an early onset HCC.
There are several details that support this hypothesis: (i) In
accordance with our and previous data that mutation of CTNNB1
is obligatory in HB pathogenesis, but not in HCC (only about 30%
are mutated) [8], all four TLCT patients harboured a CTNNB1
mutation. (ii) Except for some very rare cases (presumably mis-
classified rhabdoid tumours) HB patients have highly elevated
AFP serum levels, as opposed to 40–60% of paediatric HCC
patients [35]. The average AFP level at diagnosis of our TLCT
patients was very high (217,000 ng/ml), a level comparable to
those found in TLCT described earlier [2]. (iii) Histological exam-
ination of our four TLCT cases showed a characteristic HB histol-
ogy with predominantly foetal differentiation in all cases, but
also aspects of HCC morphology, including focal nests reminis-
cent of HCC (Fig. 2E). In case of TLCT-227, we analysed the local
recurrence, but the initial tumour was diagnosed as a pure HB,
thereby indicating that a progression towards HCC exists. (iv)
TLCT share chromosomal imbalances with HB, such as the early
gain of chromosomes 1 and 2 and gain of chromosome 8 in more
advanced HB (Fig. 2A and B). (v) Three of the patients are still
alive, which is in contrast to the poor survival rate of paediatric
HCC. (vi) HB and TLCT display comparable higher TERT expression
levels than normal liver tissue, thereby suggesting a common ori-
gin from a liver precursor cell with high self-renewal rates and
thus physiologically high telomerase activity. In contrast, HCCs
are thought to originate from normal hepatocytes that do not
cycle often and might acquire telomerase reactivation through
TERT mutations [15]. Being aware that we have only analysed a
very limited number of TLCTs, we believe that our data in sum
could support the conclusion that TLCT is a genetically derailed
progeny of HB.
Our data moreover suggest that the mutation of CTNNB1 (or
alternatively APC or AXIN1) could be the sole genetic basis of liver
tumours in early childhood, especially in light of three HB cases,
showing mutation of CTNNB1 as the only alteration. Comparably,
retinoblastoma and rhabdoid tumours have already been shown
to display a very simple genome with RB1 [36] and SMARCB1
[37] being the only recurrently mutated gene, respectively. How-
ever, introducing activating mutations of Ctnnb1 into the mouse
liver is not sufficient to drive tumourigenesis, giving rise only
to marked hepatomegaly [38,39]. Thus, additional mutations
and/or epigenetic changes may be required for HB development.
One alternative mechanism might be mutation of NFE2L2 and
more importantly activation of the NFE2L2-KEAP1 pathway.
Intriguingly, comparable alterations have been detected in HCC
in adults, showing either NFE2L2 or KEAP1 mutations in alto-
gether 7.2% [17], 8.0% [18], and 8.9% [40] of all patients, thereby
suggesting a broader role of the NFE2L2-KEAP1 pathway in liver
cancers. Although the mutations found in HB render NFE2L2
insensitive to KEAP1-mediated degradation, leading to constitu-
tive activation of the pathway, we found half of the tumour cases
show pathway activation without NFE2L2 mutations, thereby
suggesting that other yet unidentified activating mechanisms
must exist. Transcriptional downregulation of KEAP1 might be
one possibility, however we and others have failed to detect sig-
nificant differences between normal liver and liver tumour sam-
ples, although a trend for decreased KEAP1 expression in tumours
with KEAP1 mutations has been reported [18]. Accordingly, pro-
moter methylation of KEAP1, as shown for lung cancer [41], can
be dismissed too. However, as the NFE2L2 mutated cases were
concomitantly mutated in CTNNB1, as described before for adult
HCC [17], we hypothesize that activated Wnt signalling and
activated NFE2L2-KEAP1 signalling might cooperate in liver
tumourigenesis. As NFE2L2-KEAP1 signalling is known to prevent
apoptosis and promote cell survival [42], but constitutive
activation of NFE2L2-KEAP1 signalling in Keap1 knockout mice
is not sufficient to drive tumour development [43], it is tempting
to speculate that NFE2L2 may not initiate tumourigenesis,
but rather confers a high survival capacity and thereby positively
selects for already Wnt-activated premalignant cells.
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Nevertheless, further genome-wide approaches deciphering
genetic and epigenetic alterations on a larger cohort of patients
are warranted and will hopefully shed light onto the cause for
the widespread activation of the NFE2L2-KEAP1 pathway and a
possible crosstalk between Wnt and NFE2L2-KEAP1 signalling
in liver cancers.
The establishment of molecular markers to aid risk stratifica-
tion of cancer patients is an ongoing endeavour in paediatric
oncology. Here, we provide evidence that determining the activity
of the NFE2L2-KEAP1 pathway might help to identify patients at
risk for worse outcome. Accordingly, high NQO1 expression was
associated with two clinical high-risk features, namely metastatic
spread and invasive growth into vessels, and consistent with this
we found a significantly poorer outcome of high expressing
patients. In line with this, the C2 subtype of the 16-gene signature
that has been validated to predict poor prognosis in HB [9] was
also significantly associated with high NQO1 expression. Based
on these data we advocate to include the measurement of NQO1
expression into the upcoming international treatment protocol
for the pre-therapeutic risk assessment of HB patients in order
to aid risk-adapted therapy.
Collectively, our data indicate that activation of Wnt signal-
ling in concert with activation of the NFE2L2-KEAP1 pathway
might be the driving force in the development of liver cancers,
both in children and adults, thereby offering a new therapeutic
target for the treatment of these devastating diseases. Strikingly,
a first promising NFE2L2 inhibitor has recently been described,
which reduces the protein level of NFE2L2 regardless of the status
of KEAP1 or NFE2L2 being wild type or mutated [44].
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ABSTRACT
Hepatoblastoma (HB) is the most common liver tumor of childhood, usually occurring in children under
the age of 3 y. The prognosis of patients presenting with distant metastasis, vascular invasion and
advanced tumor stages remains poor and children that do survive often face severe late effects from the
aggressive chemotherapy regimen. To identify potential new therapeutics for high risk HB we used a
1,000-gene expression signature as input for a Connectivity Map (CMap) analysis, which predicted histone
deacetylase (HDAC) inhibitors as a promising therapy option. Subsequent expression analysis of primary
HB and HB cell lines revealed a general overexpression of HDAC1 and HDAC2, which has been suggested
to be predictive for the efficacy of HDAC inhibition. Accordingly, treatment of HB cells with the HDAC
inhibitors SAHA and MC1568 resulted in a potent reduction of cell viability, induction of apoptosis,
reactivation of epigenetically suppressed tumor suppressor genes, and the reversion of the 16-gene HB
classifier toward the more favorable expression signature. Most importantly, the combination of HDAC
inhibitors and cisplatin – a major chemotherapeutic agent of HB treatment - revealed a strong synergistic
effect, even at significantly reduced doses of cisplatin. Our findings suggest that HDAC inhibitors skew HB
cells toward a more favorable prognostic phenotype through changes in gene expression, thus indicating
a targeted molecular mechanism that seems to enhance the anti-proliferative effects of conventional
chemotherapy. Thus, adding HDAC inhibitors to the treatment regimen of high risk HB could potentially
improve outcomes and reduce severe late effects.
KEYWORDS
Cisplatin; connectivity map;
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Introduction
Hepatoblastoma (HB) is the most common liver tumor of
childhood, usually occurring in children under the age of
3 y.1 Over the last decades tremendous improvement has
been made in the stratification and treatment of this
highly malignant tumor. Nonetheless, patients that present
with metastases, vascular invasion or vast tumor extension
are still facing a poor outcome with overall survival rates
of only 60%.2,3 The SIOPEL 4 protocol, which was
designed to treat those high risk patients, utilizes a very
aggressive regimen of chemotherapy resulting in severe
long term side effects in surviving children.4,5 Those late
effects include cardiomyopathy, congestive heart failure
and development of second cancers from high doses of
doxorubicin as well as permanent hearing impairment and
kidney damage from platin derivatives.6-8 New targeted
treatment options hold the potential not only to improve
outcome in high risk patients, but to help minimize late
effects. Therefore, the identification of potentially drug-
gable targets in HB remains critical.
Besides clinical parameters, gene expression signatures
have shown great value in the stratification of HB.9 A 16-
gene HB classifier is able to discriminate between 2 sub-
classes of tumors and was equally effective in predicting
prognosis compared to clinical and histological tumor stag-
ing. The C1 subclass is associated with an early tumor stage
and a favorable patient outcome, whereas the C2 subclass is
tied to advanced tumor stage, metastases, vascular invasion
and poor prognosis.9
Gene expression profiles that correlate with specific phe-
notypic features of a disease are also used in the identifica-
tion of potential new treatment options utilizing biomedical
software called the Connectivity Map (CMap).10,11 CMap is
able to link gene expression patterns associated with a dis-
tinct phenotype or disease to corresponding patterns
derived from drug-treated cancer cell lines. This in silico
approach has already been successfully used to identify new
potential therapeutics for a variety of cancers.12-14
Over the last few years it became clear that epigenetic
chromatin modifiers, such as histone deacetylases (HDACs),
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play a crucial role in the development of various malignan-
cies by aberrantly silencing tumor suppressor genes.15
HDACs catalyze the removal of acetyl groups from lysine
residues on core histones. This leads to a more compact
chromatin structure, making it less accessible to specific
transcription factors and general transcription machinery as
well as altering gene expression toward cancer initiation
and progression.16 HDAC inhibition (HDACi) has shown
great promise as a treatment option of tumor entities, in
which those epigenetic regulators are overexpressed or
deregulated.16
By using CMap 10 and publically available gene expression
data 9 we identified HDAC inhibitors as one promising mole-
cule class for future therapeutic intervention of high risk HB.
We show that HDACs are overexpressed in HB primary
tumors and cell lines and that HDACi is able to reduce cell via-
bility and induce apoptosis in HB cells. Furthermore, we dem-
onstrate that HDACi also leads to re-expression of HB-specific
tumor suppressor genes and attenuation of the adverse C2 sub-
class 16-gene expression in HB cells. Finally, we reveal novel
therapeutic synergies between cisplatin and HDAC inhibitors,
which increase the efficacy of the treatment and lead to a sub-
stantial dose reduction of cisplatin. These findings suggest that
HDACi is a potential new therapy option for high risk HB.
Results
Connectivity map identifies HDAC inhibitors as potential
treatment option of high risk HB
To identify new treatment options for high risk HB we used
the Connectivity Map (CMap), a bioinformatic tool that
shows functional connections between drugs and gene
expression signatures of diseases.10 We built an expression
signature from existing data derived from 13 primary HB.9
The signature contained 1,000 genes that best discriminated
the high risk-related C2 subtype from the standard risk-
related C1 subtype of HB (Suppl. Table 1). C2 tumors
within this cluster were associated with poor survival, dis-
tant metastasis, vascular invasion, and advanced PRETEXT
stages (Fig. 1A). We then used the discriminating signature
as an input query for CMap and specifically looked for
compounds with negative correlation scores, indicating
potential therapeutic value for high risk patients. Out of
1,309 compounds represented by CMap, 2 known inhibitors
of PI3K/AKT signaling that have already shown therapeutic
effects in HB,17,18 namely LY-294002 and sirolimus, were
highly ranked in the CMap screen (Table 1), thereby under-
scoring the capability of Cmap in identifying relevant drugs.
More interestingly, 2 known HDAC inhibitors were within
Figure 1. (A) Hierarchical clustering of the 1,000 best discriminating genes between the standard risk C1 and the high risk C2 HB subclasses. Important clinicopathological
characteristics are depicted below. A detailed list of the genes can be found in Suppl. Table 1. (B) Bar graphs represent the Connectivity Score data for vorinostat (SAHA)
and trichostatin A (TSA). The black horizontal lines represent each instance performed with the respective compound. Instances in the red area indicate negative correla-
tion scores and instances in the green area positive ones. No correlation can be detected for instances in the gray area.
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the top matches for the C2 signature (Table 1), namely vor-
inostat (SAHA) and trichostatin A (TSA). When we plotted
the individual correlation scores of the C2 signature for all
instances comprising SAHA treatments (12 in CMap) and
TSA treatments (182 in CMap), we found them predomi-
nantly to be negative (Fig. 1B). This data suggests that
HDAC inhibitors can reverse the C2 signature and might
therefore constitute a suitable new treatment option of high
risk HB.
HDACs are overexpressed in HB
As high expression levels of HDACs have been suggested as a
positive predictor for the efficacy of HDAC inhibition
(HDACi) as a treatment option,19 we determined the expres-
sion levels of class I (HDAC1, HDAC2 and HDAC3) and class
IIa HDACs (HDAC4, HDAC5 and HDAC7) in 30 primary HB,
5 liver tumor cell lines and 10 non-tumor liver samples. We
found that HDAC1, HDAC2 and HDAC4 are generally overex-
pressed in primary HB compared to normal liver expression,
with HDAC1 and HDAC2 being also overexpressed in HB cell
lines (Fig. 2A). Interestingly, we found tumors exhibiting the
high risk C2 signature to be significantly correlated with high
expression levels of HDAC 1 and 2 (Fig. 2B). These findings
suggest that HB exhibit a strong overexpression of several
HDACs, especially of class I that are known to be associated
with higher tumor grades, aggressive phenotypes and poor
prognosis in other solid tumors.20,21
HDACi inhibits growth and induces apoptosis in HB cells
To investigate the effect of HDACi on HB cells, we evaluated
the impact of 2 HDAC inhibitors as a monotherapy on the via-
bility of various liver tumor cell lines and fibroblasts as a con-
trol, namely SAHA, a pan inhibitor that is able to block the
activity of all HDAC subclasses and MC1568, a subclass inhibi-
tor that blocks only class IIa HDACs. Treatment with SAHA
resulted in a potent reduction of cell viability in a dose depen-
dent manner (Fig. 3A). Monotherapy of HB cells with MC1568
affected cell viability only at its highest concentration (10mM).
Although expression levels of HDAC4 (class IIa) are high in
the primary tumors, they are surprisingly low in the cell lines
(Fig. 2A), which might explain the ineffectiveness of class IIa
inhibition in vitro. Both HDAC inhibitors showed little or no
effect on the non-cancerous fibroblasts, suggesting a selective
effect of HDACi on liver tumor cells through inhibition of class
I HDAC activity.
In order to see how HDAC inhibitors convey their anti-pro-
liferative effects in liver tumor cells we conducted cell cycle and
apoptosis analyses. Cells showed only minimal changes in cell
cycle progression when treated with either SAHA or MC1568
(Fig. 3B). Interestingly, SAHA treated cells showed a strong
induction of apoptosis (Fig. 3B). MC1568 did also induce apo-
ptosis, but to a much lower extent (Fig. 3B). Additional protein
analysis unveiled high levels of cleaved PARP after cells under-
went HDACi, furthering the assumption that HDAC inhibitors
convey their anti-proliferative capabilities rather through
induction of apoptosis than cell cycle arrest (Fig. 3C).
Given the fact that the overexpression of HDACs in tumors
has been identified as a key factor of aberrant epigenetic tumor
suppressor silencing,22 we examined the expression levels of
genes epigenetically silenced in HB 23-25 after treatment with
HDAC inhibitors. We found hedgehog-interacting protein
(HHIP), secreted frizzeled-related protein 1 (SFRP1) and insu-
lin-like growth factor-binding protein 3 (IGFBP3) to be
strongly re-expressed upon HDACi in most cell lines (Fig. 3D),
thereby suggesting that the pro-apoptotic effect of HDAC ther-
apy is functionally linked to restored tumor suppressor
expression.
HDACi is able to change the unfavorable gene expression
signature in HB cells
The results of the CMap analysis suggest that HDAC inhibitors
can potentially reverse the unfavorable C2 expression signature
toward the prognostic more favorable C1 signature, virtually
turning a high risk HB into a standard risk HB with a better
response to therapy and a better outcome. In order to validate
the prognostic value of this system for our cohort of 30 primary
tumors, we first tested for correlations between HB-subclass
(C1/C2) and clinicopathological characteristics. We found that
tumors of the C2 subclass were in fact significantly associated
with poor survival (Fig. 4A), metastasis, vascular invasion,
advanced SIOPEL stage and the unfavorable embryonal histo-
type (Table 2). As high expression of the genes RPL10A, E2F5,
NLE1, BUB1, DLG7, IGSF1, AFP and DUSP9 is characteristic
of high risk C2 subclass tumors,9 we analyzed various liver
tumor cell lines that initially show the adverse C2 expression
profile after treatment with HDAC inhibitors. In line with the
CMap data, we found a strong decrease in expression of most
of those genes upon treatment, suggesting a shift from the high
risk C2 signature (associated with high expression of the indi-
cated genes) to the standard risk C1 signature (associated with
low expression levels of the indicated genes) (Fig. 4B).
Combination of HDACi and cisplatin show strong synergies
Recent studies suggest that HDAC overexpression is responsi-
ble for chemoresistance in solid tumors 19,26 and that HDAC
inhibitors can sensitize those tumors to conventional chemo-
therapy, especially to cisplatin.27,28 As a proof of concept, we
combined each HDAC inhibitor and cisplatin at various con-
centrations and compared the effects on cell viability with those
Table 1. Results of Connectivity Map analysis.
Rank CMap name mean n enrichment P-value Percent
1 vorinostat ¡0.541 12 ¡0.475 0.005 100
2 thioridazine ¡0.492 20 ¡0.434 <0.001 90
3 prochlorperazine ¡0.489 16 ¡0.374 0.017 87
4 chlorpromazine ¡0.474 19 ¡0.343 0.017 84
5 trifluoperazine ¡0.473 16 ¡0.420 0.005 75
6 a-estradiol ¡0.452 16 ¡0.330 0.047 81
7 trichostatin A ¡0.426 182 ¡0.286 <0.001 85
8 fluphenazine ¡0.426 18 ¡0.322 0.039 83
9 tretinoin ¡0.396 22 ¡0.303 0.027 81
10 15-delta prostaglandin J2 ¡0.372 15 ¡0.401 0.011 66
11 LY-294002 ¡0.371 61 ¡0.260 <0.001 72
12 tanespimycin ¡0.358 62 ¡0.212 0.007 72
13 sirolimus ¡0.311 44 ¡0.242 0.010 70
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of a combination of doxorubicin and cisplatin, which consti-
tutes the SIOPEL4 regimen.5 When we analyzed the viability
data of the combinational therapy and compared them to the
monotherapy data of each individual compound by using the
CompuSyn software, which is able to identify synergies
between 2 compounds, we found synergistic effects between
the HDAC inhibitors and cisplatin in all cell lines and at most
concentrations (Fig. 5A). Notably, only few synergies were
detected between doxorubicin and cisplatin.
When we looked at cell viability we found that combinations
of cisplatin and SAHA were equally effective compared to com-
binations of cisplatin and doxorubicin (data not shown). We
found the strongest synergies between 5mM cisplatin and vari-
ous concentrations of SAHA. Combinations at this particular
concentration appear to be slightly superior to the combination
of cisplatin and doxorubicin at equal concentrations in regard
to cell viability (Fig. 5B). While MC1568 and cisplatin combi-
nations also showed a considerable effect on cell viability, it did
not achieve the effect of cisplatin and doxorubicin combina-
tions at any concentration.
Discussion
Since standard risk HB patients can achieve good outcomes
with already existing therapy regimens,2 we focused our
research on the discovery of new treatment options for high
risk patients, whose outcome still remains poor with the cur-
rent treatment strategies.3,5 Using CMap, we identified HDAC
inhibitors as potential new drugs for the treatment of high risk
HB. Interestingly, previous studies have already shown anti-
proliferative effects of HDACi in vitro 29-31 and in preclinical
mouse models of hepatocellular carcinoma (HCC),32 the most
common liver tumor in adults with a considerably poor out-
come. Consequently, the pan HDAC inhibitor belinostat has
recently been tested in a clinical phase I/II trial for patients
with unresectable HCC, which resulted in disease stabilization
with a tolerable toxicity profile.33 Moreover, as phase I clinical
trials have already demonstrated the safe use of SAHA in pedi-
atric populations,34,35 based on earlier preclinical in vitro stud-
ies using SAHA with doses similar to the ones in our
experiments,36-38 it could be emphasized that these doses are
Figure 2. (A) HDAC expression levels of normal liver, primary HB and liver tumor cell lines (CL). Expression of class I and class IIa HDACs were measured by qRT-PCR and
normalized to the expression of the house-keeping gene TBP. Statistical significance was calculated for differences between normal liver tissue and tumors and tumor
cell lines using t-test. (B) HDAC expression levels of primary HB after their stratification as standard (C1) or high risk HB (C2) according to the 16-gene HB classifier. Statisti-
cal significance was calculated for differences between C1 and C2 tumors using t-test.
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clinically achievable and tolerable. Thus, our findings are in line
with studies in HCC and support the concept of HDACi as a
promising treatment strategy for liver malignancies, both in the
adult and pediatric population.
Our systematic expression analysis of a large set of primary HB
and liver tumor cell lines revealed that HDACs are generally upre-
gulated compared to normal liver tissue. Overexpression of
HDAC2 has been suggested as a positive predictive marker for the
response of solid tumors to treatment withHDAC inhibitors.19,39,40
Treatment of liver tumor cells with HDAC inhibitors seem to sup-
port this theory, given the fact that the cell lines with high HDAC2
expression (HUH6 and HUH7) were most responsive to HDACi,
whereas cell lines with normal HDAC2 expression (HepG2 and
HepT1) responded poorly to the monotherapy regimen. However,
Figure 3. (A) Cell viability of HB cell lines and fibroblasts as evaluated by MTT assay after 48 h treatment with indicated concentrations of MC1568 and SAHA. Values rep-
resent means§ standard deviation of 3 independent experiments performed in duplicates. (B) Cell cycle distribution (left panel) and apoptosis (right panel) of liver tumor
cell lines were analyzed by flow cytometry 48 h after treatment with vehicle (DMSO), 10mM of MC1568 and 1mM (HUH6, HepT1 and HepG2) or 2mM of SAHA (HUH7). (C)
Western blot analysis for cleaved PARP in indicated HB cell lines after 48 h of treatment with DMSO, MC1568 and SAHA (concentrations as in B). (D) Expression levels of
the tumor suppressor genes SFRP1, HHIP, and IGFBP3 in liver tumor cell lines after HDACi. Expression levels were measured after 48 h of treatment by qRT-PCR and nor-
malized to the expression of the house-keeping gene TBP. Indicated are fold changes to the individual DMSO control.
Figure 4. (A) Overall survival was calculated as time from diagnosis to death of the disease and is plotted for 30 HB patients. Statistical significance was calculated using
the Mantel-Cox test. (B) Cell lines expressing the adverse C2 signature were treated with 10mM of MC1568, 1mM (HUH6, HepT1 and HepG2) and 2mM (HUH7) of SAHA,
or vehicle (DMSO). Graphs show decreased expression levels in percent of 8 high risk C2 signature genes of the indicated genes upon 48 h of treatment with the indicated
HDAC inhibitors.
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ifHDAC2 has the potential to be used as a biomarker for predicting
clinical responses to HDACIs, as shown for HR23B in adult
HCC,33 has to be confirmed in future studies.
The changes induced by HDACi in the gene expression of
HB cells that initially showed the adverse C2 signature not only
underlines the predictive power of the CMap by partially
reversing this signature, but also suggests a specific benefit of
HDACi for patients with high-risk HB. Since our analysis
showed a strong association between the C2 signature of pri-
mary tumors and clinicopathological features, such as poor sur-
vival, metastasis, vascular invasion and advanced tumor stage, a
HDACi induced change in gene expression toward the more
favorable C1 signature could potentially lead to a better out-
come and an enhanced response to treatment.
Late effects of chemotherapy constitute an increasing prob-
lem, given the tremendous progress that has been made in
achieving better long-term survival rates for children with can-
cer. Doxorubicin, the chemotherapeutic currently used to esca-
late the therapy of high-risk HB, is among the agents with the
most severe late effects such as cardiomyopathy, congestive
heart failure and development of secondary malignancies.4,8
Our data suggest that doxorubicin can possibly be replaced
with the HDAC inhibitor SAHA as the escalating agent for the
high risk HB group in addition to the cisplatin backbone, with-
out compromising the efficacy of the treatment. Furthermore,
HDAC inhibitors, especially SAHA, have shown great promise
in overcoming chemoresistance in solid tumors. Studies pro-
vide evidence that HDACi can sensitize tumor cells for chemo-
therapeutics, especially cisplatin.26,27 The strong synergies we
found between SAHA and cisplatin hold the potential to reduce
cisplatin concentrations, which would further diminish the late
effects caused by this agent, namely permanent hearing
impairment and kidney damage.4,6,7
While further studies are warranted to reveal whether
HDACi also represents a successful treatment option in vivo,
which could be preclinically tested in genetic or patient-derived
xenograft mouse models, our data suggest a direct benefit of
HDACi for children with high-risk HB through a more targeted
approach. This could potentially open up new therapeutic
opportunities for future clinical studies in which substituting
conventional chemotherapeutic agents with HDACi could
reduce detrimental long-term side effects in patients.
Patients and methods
Connectivity map analysis
Expression profiling data from 13 primary HB with defined his-
tological and clinical annotations (Suppl. Table 3) were
obtained from ArrayExpress (http://www.ebi.ac.uk/microarray-
as/ae/) under the accession numbers E-MEXP-1851.9 After
using this data to identify the most differentially expressed
genes between previously defined standard risk tumors (C1)
and high risk tumors (C2), we built a gene expression profile
containing the 1,000 best discriminating genes between these 2
subclasses (Suppl. Table 1). We entered this signature into the
latest dataset of CMap (Build 02) and compared it to more
than 7,000 so-called instances, which are defined by expression
profiles of human cancer cell lines treated with 1,309 therapeu-
tic compounds at different concentrations (http://www.broadin
stitute.org/cmap). Each instance was assigned a connectivity
score from ¡1 to 1, representing the relative association of the
respective instance with the specific query. A positive connec-
tivity score indicates that a drug is able to induce the input
Table 2. Association between C1/C2 classification and clinicopathological features
of HB.
Factors No. of tumors C1 C2 P-value
Sex 0.715
Male 15 7 8
Female 15 8 7
Age at diagnosis (months) 0.232
<36 21 12 9
>36 9 3 6
Histological type 0.003
Fetal 23 15 8
Embryonal 7 0 7
Stage (PRETEXT) 0.068
1–3 24 14 10
4 6 1 5
SIOPEL risk group 0.001
Standard risk 15 12 3
High risk 15 3 12
Outcome 0.013
Alive 22 14 8
Dead 8 1 7
Metastasis 0.003
No 16 12 4
Yes 14 3 11
Vascular invasion 0.031
No 23 14 9
Yes 7 1 6
Multifocality 0.409
No 22 12 10
Yes 8 3 5
Figure 5. (A) Cell lines were treated with the indicated concentrations of cisplatin
combined with various concentration of either doxorubicin, MC1568 or SAHA. Cell
viability was measured after 48 h and combination indices (CI) were calculated
from 2 independent experiments performed in duplets. CI < 0.1 D very strong
synergism, CI< 0.3D strong synergism, CI< 0.7D synergism, CI<1 D slight syn-
ergism, CI  1 no synergism. (B) Cell lines were treated with the indicated concen-
trations of cisplatin combined with 5mM of either doxorubicin, MC1568 or SAHA.
Cell viability was measured after 48 h from 2 independent experiments performed
in duplets.
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signature in human cell lines. Conversely, a negative connectiv-
ity score indicates that a drug is able to reverse the input signa-
ture. Since we used the high risk C2 signature as input, we
looked for negative connectivity scores, which indicate poten-
tial therapeutic value. After rank-ordering all instances, the
connectivity score of various instances of the same compound
were averaged and filtered by the number of instances (n >10)
and P-value (<0 .05).
Patients and materials
A total of 30 liver tumor specimens were obtained from
pediatric patients undergoing surgical resection in our
department. Matching normal liver was available from 10
patients. Written informed consent was obtained from each
patient, and the study protocol was approved by the Com-
mittee of Ethics of the Ludwig-Maximilians-University of
Munich. We used the 4 human HB cell lines HepT1,
HepT3 (both provided by Dr. T. Pietsch), HepG2 (ATCC,
Manassas, VA, USA), and HUH6 (Japanese Collection of
Research Bioresources, Osaka, Japan), the hepatocellular
carcinoma cell line HUH7 (kindly provided by Dr. Enrico
de Toni), as well as human fibroblasts, which were obtained
from a skin biopsy of a healthy male volunteer. Cells were
grown at 37C in RPMI medium containing 10% FCS, 1%
antibiotics and glutamine supplement.
Real-time reverse transcription polymerase chain reaction
RNA extraction and purification, cDNA synthesis, PCR ampli-
fications and quantization of gene expression were performed
as described before 25 using the primer pairs outlined in Suppl.
Table 2. Amplification of the house-keeping gene TATA-Box-
binding-Protein (TBP) was performed to standardize the
amount of sample RNA.
Proliferation assays and detection of synergy
Cell proliferation was assessed using 1-(4,5-dimethylthiazol-
2-yl)-3,5-diphenylformazan (MTT) assays. Cells were seeded
at a density of 10,000 cells per well into 96 well plates
(NUNC, Langenselbold, Germany). After overnight attach-
ment, cells were treated for 48 hours with various concen-
trations of suberoylanilide hydroxamic acid (SAHA, Sigma-
Aldrich, Steinheim, Germany), MC1568 (Selleck Chemicals,
Munich, Germany), cisplatin (Selleck Chemicals), doxorubi-
cin (Selleck Chemicals), DMSO (Sigma-Aldrich) or various
combinations of those compounds. To assess cell viability,
the optical density was measured at a wavelength of
595 nm after the addition of MTT using the GENios multi
scanner microplate reader (TECAN, M€annedorf, Switzer-
land). Synergy testing of the combined treatment was ana-
lyzed using the CompuSyn software (http://www.combosyn.
com/), which utilizes the Chou-Talalay method.41 The calcu-
lated combination index (CI) was used as a quantitative mea-
sure of the degree of interaction between 2 drugs. CI D 1
indicates additivity, CI > 1 indicates antagonism, and CI < 1
indicates synergism.
Apoptosis and cell cycle analysis
Cells were seeded in 6 well plates and after 24 hours, exposed to
DMSO, SAHA or MC1568 at various concentrations for
48 hours. Fixation and permeabilization of cells were per-
formed by dropwise addition of 70% ethanol while vortexing
and incubation at ¡20C for at least 2 hours. Permeabilized
cells were washed with PBS and DNA was stained using
0.02 mg/ml propidium iodide (Sigma-Aldrich) and 0.2 mg/ml
RNaseA (Qiagen, Hilden, Germany) in PBS/0.1%Triton X-100
(Sigma-Aldrich) for 30 minutes at room temperature in the
dark. Cell cycle was analyzed via BD-LSRFORTESSA flow
cytometer (BD Biosciences, San Jose, CA, USA) and using
Flowing software 2.5.1 (http://www.flowingsoftware.com/).
Western blot
Cells were seeded at a density of 1 £ 106 per 10 cm cell
culture dish. After overnight attachment cells were treated
for 48 hours with SAHA, MC1568 or DMSO at various
concentrations. After treatment non-adherent cells and
adherent cells were pooled together in ice-cold lysis buffer
(0.5% Triton-X100, 1 mM orthosodiumvanadate, cOmplete
Mini protease inhibitor (Roche Diagnostics, Penzberg, Ger-
many)). Protein lysates were incubated on ice for 20 minutes
under occasional vortexing. After centrifugation for
30 minutes at 4C protein lysates without cell debries were
stored at 4C until use. The protein concentration was
determined by the Bio-Rad Protein Assay (M€unchen, Ger-
many). Proteins (20 mg) were loaded on a 4–12% BIS TRIS
NuPage Gel (Novex by Life Technologies, Carlsbad, CA,
USA) separated under reducing conditions and transferred
to nitrocellulose blotting membrane (GE Healthcare Life
Sciences, Freiburg, Germany). Thereafter, membranes were
blocked with PBS/0.1% Tween20 and 5% non-fat dry milk
for 2 hours at room temperature. First, antibodies rabbit
anti-human poly(ADP-ribose) polymerase (PARP) (1:1,000)
or rabbit anti-human b-actin (1:2,500) (all from Cell Signal-
ing Technology, Leiden, Netherlands) were added over
night at 4C. For detection, membranes were incubated for
1 hour at room temperature with horseradish peroxidase-
conjugated polyclonal goat anti-rabbit immunoglobulin sec-
ondary antibody (Dako, Glostrup, Denmark) and signals
were captured using the enhanced Western blotting reagent
detection system (GE Healtcare, Buckinghamshire, UK).
Statistical analyses
Data were expressed as means C standard deviation (SD) and
statistically subjected to Student’s unpaired t-test. Kaplan-
Meier estimates of specific survival time in the various groups
were compared using the log-rank Mantel-Cox test. A level of
P < 0.05 was considered to be significant, P < 0.01 highly
significant.
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